Alembic Pharma gets US FDA nod for generic Doryx tablets

Alembic Pharma gets US FDA nod for generic Doryx tablets

By, Admin 1 May 2022

Alembic Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for doxycycline hyclate delayed-release tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg. The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Doryx tablets, 75 mg, 100 mg, 150 mg and 200 mg, of Mayne Pharma International, stated Alembic Pharma in a statement. Doxycycline hyclate delayed-release tablets are indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of other antibacterial drugs. These tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying anti-bacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy, the statement said. Doxycycline hyclate delayed-release tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg have an estimated market size of USD 10 million for twelve months ending September 2021 as per IQVIA.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!